Matinas Biopharma

MTNBPhase 3

Bedminster, United Statesmatinasbiopharma.com

Matinas BioPharma is focused on overcoming significant drug delivery challenges through its disruptive Lipid Nano-Crystal (LNC) platform, which enables oral, intracellular delivery of complex molecules. The company's most advanced program, MAT2203, aims to transform the treatment of invasive fungal infections by offering an oral, less toxic alternative to intravenous amphotericin B. With a robust IP portfolio, a scalable GMP manufacturing facility, and a pipeline extending into oncology and inflammation, Matinas is positioning its platform technology for broad therapeutic application and potential partnerships.

Market Cap

$246.6M

Focus

Small Molecules

MTNB · Stock Price

USD 38.50+6.00 (+18.46%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Lipid Nano-Crystal (LNC) platform enabling safe, targeted, intracellular, and oral delivery of small molecules and small oligonucleotides (siRNA, ASOs) via unique cochleate structures.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Placebo + MAT9001 (omega-3 pentaenoic acid)	Severe Hypertriglyceridemia	Phase 3
MAT2203 + Amphotericin B	Cryptococcal Meningitis	Phase 3
Amphotericin B	Candidiasis, Chronic Mucocutaneous	Phase 2
Oral Encochleated Amphotericin B (CAMB) + Fluconazole	Vulvovaginitis	Phase 2
Oral Encochleated Amphotericin B (CAMB)	Acute Myeloid Leukemia	Phase 2

Funding History

Total raised: $55M

PIPE$30MUndisclosedJun 15, 2020

IPO$20MUndisclosedFeb 15, 2015

Series A$5MUndisclosedMar 15, 2013

Opportunities

The primary growth opportunity is the successful development and commercialization of MAT2203 as the first oral, broad-spectrum fungicidal agent, addressing a significant unmet need.

A larger, platform-driven opportunity exists in leveraging the LNC technology to enable oral delivery of oligonucleotide therapeutics (siRNA, ASO) for high-value targets in inflammation and oncology, potentially through strategic partnerships.

Risk Factors

Key risks include clinical trial failure of MAT2203, the need for frequent capital raises leading to shareholder dilution (highlighted by a recent NYSE non-compliance notice), and the unproven clinical translation of the LNC platform for delivering novel payloads like oligonucleotides in humans.

Competitive Landscape

MAT2203 competes against IV amphotericin B formulations and newer antifungals, differentiating via oral delivery and improved safety. The LNC platform competes with other drug delivery technologies (e.g., LNPs, GalNAc), differentiating through its oral bioavailability, natural lipid composition, and unique cell membrane fusion mechanism for intracellular delivery.